XML 69 R62.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Schedule of Segment Information, Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 52,443 $ 41,873
Cost of revenue 16,979 18,051
Research and development 24,203 30,245
Sales and marketing 23,047 22,319
General and administrative 17,399 19,597
Adjusted EBITDA [1] (12,748) (28,180)
Operating Segments | MRD    
Segment Reporting Information [Line Items]    
Revenue 43,721 32,626
Cost of revenue 15,885 15,921
Research and development 9,159 12,924
Sales and marketing 21,413 20,385
General and administrative 9,502 10,656
Items to reconcile net loss to Adjusted EBITDA [1] 8,127 10,001
Adjusted EBITDA [1] (4,111) (17,259)
Operating Segments | Immune Medicine    
Segment Reporting Information [Line Items]    
Revenue 8,722 9,247
Research and development 15,044 17,321
Items to reconcile net loss to Adjusted EBITDA [1] 6,035 7,666
Adjusted EBITDA [1] (5,446) (6,927)
Unallocated Corporate    
Segment Reporting Information [Line Items]    
Adjusted EBITDA [1] (3,191) (3,994)
Unallocated Corporate | Immune Medicine    
Segment Reporting Information [Line Items]    
Other segment items [2] $ 5,159 $ 6,519
[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[2] Includes all Immune Medicine operating expenses, other than research and development expenses.